The clinical significance of detection of residual disease in childhood ALL

Critical Reviews in Oncology/Hematology

Volumn 28, Issue 1, 1998, Pages 31-55

  Faderl, Stefan ^a   Estrov, Zeev ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER DIAGNOSIS; CHILD; CHILDHOOD LEUKEMIA; CLONOGENIC ASSAY; GENE REARRANGEMENT; HUMAN; IMMUNOPHENOTYPING; KARYOTYPING; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; REVIEW;

EID: 0032102434     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(98)00008-0     Document Type: Article

References (197)

1. [1] Rivera GK, Crist WM. Acute lymphoblastic leukemia. In: Handin RI, Lux SE, Stossel TP, editors. Blood, Principles and Practices of Hematology, 1st edn. Philadelphia, PA: J.B.Lippincott, 1995:743-82.
2. [2] Pinkel D. Lessons from 20 years of curative therapy of childhood acute leukaemia. Br J Cancer 1992;65:148-53.
3. [3] Rivera GK, Pinkel D, Simone JV, et al. Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. New Engl J Med 1993;329:1289-95.
4. [4] Pui CH, Dodge RK, Look AT, et al. Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St Jude Total Therapy Studies VIII, IX, and X. J Clin Oncol 1991;9:1341-7.
5. [5] Bennett JM, Catovsky D, Daniel MT, et al. The French-American-British (FAB) Cooperative Group. Proposals for the classification of the acute leukaemias. Br J Haematol 1976;33:451-8.
6. [6] Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-8.
7. [7] Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995;6:1416-34.
8. [8] Ryan DH, Van Dongen JJM. Detection of residual disease in acute leukemia using immunological markers. In: Bennett JM, Foon KA, editors. Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias. Norwell, MA: Kluwer Academic, 1988:173-207.
9. [9] Van Bekkum DW. Reflection on the detection and treatment of leukemia. In: Lowenberg B, Hagenbeck A, editors. Minimal Residual Disease in Acute Leukemia. Boston, MA: Martinus Nijoff, 1984:385-90.
10. [10] Cole-Sinclair MF, Foroni L, Hoffbrand AV. Genetic changes: relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia. Baillières Clin Haematol 1994;7:183-233.
11. [11] Salloum E, Pico JL, Herait P, et al. Very late recurrence of childhood acute lymphoblastic leukemia treated with chemoimmunotherapy: a report of three cases occurring 19, 11 and 9 years after discontinuation of chemotherapy. Med Pediatr Oncol 1989;17:155-8.
12. [12] Nizet Y, Van Daele S, Lewalle P, et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 1993;82:1618-25.
13. [13] Potter MN, Steward CG, Oakhill A. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. Br J Haematol 1993;83:412-8.
14. [14] Rhagavachar A, Thiel E, Bartram CR. Analysis of phenotype and genotype in acute lymphoblastic leukemia at presentation and relapse. Blood 1987;70:1083-97.
15. [15] Estrov Z, Roberts WM, Zipf T. Residual disease in acute lymphoblastic leukemia of childhood. Detection, quantitation, characterization and clinical significance. Int J Pediatr Hematol Oncol, in press.
16. [16] Estrov Z, Grunberger T, Dubé ID, et al. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. New Engl J Med 1986;315:538-42.
17. [17] Roberts WM, Estrov Z, Kitchingman GR, et al. Detection of minimal residual disease in ALL: biology, methods, and applications. In: Freireich EJ, Kantarjian H, editors. Molecular Genetics and Therapy of Leukemia. Boston, MA: Kluwer Academic, 1996:149-66.
18. [18] Van Dongen JJM, Breit TM, Adriaansen HJ, et al. Immunophenotypic and immunogenotypic detection of minimal residual disease in acute lymphoblastic leukemia. In: Ludwig WD, Thiel E, editors. Recent Results in Cancer Research. Berlin: Springer, 1993:157-84.
19. [19] Van Dongen JJM, Breit TM, Adriaansen HJ, et al. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992;6 (Suppl 1):47-59.
20. [20] Bartram CR, Yokota S, Hansen-Hagge TE, et al. Detection of minimal residual leukemia by polymerase chain reactions. Bone Marrow Transpl 1990;6 (Suppl):4-8.
21. [21] Campana D, Yokota S, Coustan-Smith E, et al. The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction. Leukemia 1990;4:609-14.
22. [22] Rogers PCJ, Bleyer WA, Coccia P, et al. Yield of unpredicted bone-marrow relapse diagnosed by routine marrow aspiration in children with acute lymphoblastic leukaemia. A report from the Children's Cancer Study Group. Lancet 1984;1:1320-32.
23. [23] Haworth C, Heppleston AD, Morris-Jones PH, et al. Routine bone marrow examination in the management of acute lymphoblastic leukaemia of childhood. J Clin Pathol 1981;34:483-5.
24. [24] Komp DM, Fischer DB, Sabio H, et al. Frequency of bone marrow aspirates to monitor acute lymphoblastic leukaemia in childhood. J Pediatr 1983;102:395-7.
25. [25] Borella L, Green AA, Webster RG. Immunological rebound after cessation of long-term chemotherapy in acute leukemia. Blood 1973;40:42-51.
26. [26] Bradstock KF, Papageorgiou ES, Janossy G. Diagnosis of meningeal involvement in patients with acute lymphoblastic leukaemia: immunofluorescence for terminal transferase. Cancer 1981;47:2478-81.
27. [27] Bernell P, Arvidsson I, Jacobsson B, et al. Fluorescence in situ hybridization in combination with morphology detects minimal residual disease in remission and heralds relapse in acute leukaemia. Br J Haematol 1996;95:666-72.
28. [28] Wang JCY, Beauregard P, Soamboonsrup P, et al. Monoclonal antibodies in the management of acute leukemia. Am J Hematol 1995;50:188-99.
29. [29] Campana D, Coustan-Smith E, Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood 1990;76:163-71.
30. [30] Terstappen LWMM, Loken MR. Five dimensional flow cytometry as a new approach for blood and bone marrow differentials. Cytometry 1988;9:548-53.
31. [31] Campana D, Coustan-Smith E. The use of flow cytometry to detect minimal residual disease in acute leukemia. Eur J Histochem 1996; 40 (Suppl 1):39-42.
32. [32] Campana D, Coustan-Smith E, Behm FG. The definition of remission in acute leukemia with immunolgic techniques. Bone Marrow Transpl 1991;8:429-37.
33. [33] Janossy G, Campana D, Burnett A, et al. Autologous bone marrow transplantation in acute lymphoblastic leukemia-preclinical immunologic studies. Leukemia 1988;2:485-95.
34. [34] Gross HJ, Verwer B, Houck D, et al. Detection of rare cells at a frequency of one per million by flow cytometry. Cytometry 1993;14:519-24.
35. [35] Rhese MA, Corpuz S, Heimfeld S, et al. Use of fluorescence threshold triggering and high-speed flow cytometry for rare event detection. Cytometry 1995;22:317-22.
36. [36] Greaves MF, Delia D, Janossy G, et al. Acute lymphoblastic leukaemia associated antigens. IV. Expression on non-leukaemic lymphoid cells. Leuk Res 1980;4:15-21.
37. [37] Janossy G, Bollum FJ, Bradstock KF, et al. Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations. Blood 1980;56:430-41.
38. [38] Greaves MF. Differentiation-linked leukemogenesis in lymphocytes. Science 1986;234:697-704.
39. [39] Reading CL, Estey EH, Huh YO, et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993;81:3083-7.
40. [40] Hurwitz CA, Gore SD, Stone KD, et al. Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells. Leukemia 1992;6:233-8.
41. [41] Janossy G, Tidman N, Papageorgiou ES, et al. Distribution of T lymphocyte subsets in the human bone marrow and thymus: an analysis with monoclonal antibodies. J Immunol 1981;126:1608-13.
42. + cells in the blood and bone marrow: implications for surveillance of residual leukemia. Blood 1989;74:312-9.
43. [43] Campana D, Thompson JS, Amlot P, et al. The cytoplasmic expression of CD3 antigens in normal and malignant cells of T lymphoid lineage. J Immunol 1987;138:648-55.
44. [44] Campana D. Applications of cytometry to study acute leukemia: In vitro determination of drug sensitivity and detection of minimal residual disease. Cytometry 1994;18:68-74.
45. [45] Vogler LB, Crist WM, Bockman DE, et al. Pre-B leukaemia: a new phenotype of childhood lymphoblastic leukaemia. New Engl J Med 1978;298:872-7.
46. + B-cell acute lymphoblastic leukemia (B-ALL) without Burkitt characteristics. Br J Haematol 1988;68:423-6.
47. [47] Potter MN, Cross NC, Van Dongen JJM, et al. Molecular evidence of minimal residual disease after treatment for leukemia and lymphoma: an update meeting report and review. Leukemia 1993;7:1302-14.
48. [48] Foot ABM, Potter MN, Ropner JE, et al. Transient erythroblastopenia of childhood with CD10, TdT, and cytoplasmic μ lymphocyte positivity in bone marrow. J Clin Pathol 1990;43:857-9.
49. [49] Hooijkaas H, Hählen K, Adriaansen HJ, et al. Terminal deoxynucleotidyl transferase (TdT)-positive cells in cerebrospinal fluid and development of overt CNS leukemia: a 5-year follow-up study in 113 children with a TdT-positive leukemia or non-Hodgkin's lymphoma. Blood 1989;74:416-22.
50. [50] Homans AC, Barker BE, Forman EN, et al. Immunophenotypic characteristics of cerebrospinal fluid cells in children with acute lymphoblastic leukemia at diagnosis. Blood 1990;76:1807-11.
51. [51] Pui CH, Raimondi SC, Behm FG, et al. Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia. Blood 1986;68:1306-10.
52. [52] Bernard A, Raynal B, lemerle J, et al. Changes in surface antigens on malignant T cells from lymphoblastic lymphomas at relapse: an appraisal with monoclonal antibodies and microfluorometry. Blood 1982;59:809-15.
53. [53] Stass S, Mirro J, Melvin S, et al. Lineage switch in acute leukemia. Blood 1984;64:701-6.
54. [54] Martens ACM, Schultz FW, Hagenbeek A, et al. Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease. Blood 1987;70:1073-8.
55. [55] Cavé H, Guidal C, Rohrlich P, et al. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of δ and γ T-cell receptor genes. Blood 1994;83:1892-902.
56. [56] Anderson CL, Looney RJ. Human leukocyte IgG Fc receptors. Immunol Today 1986;7:264-6.
57. [57] Williams DL, Raimondi S, Rivera G, et al. Presence of clonal chromosome abnormalities in virtually all cases of acute lymphoblastic leukemia. New Engl J Med 1985;313:640-641, letter.
58. [58] Secker-Walker LM, Prentice HG, Durrant J, et al. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. Br J Haematol 1997;96:601-10.
59. [59] Secker-Walker LM, Lawler SD, Hardisty RM. Prognostic implications of chromosomal findings in acute lymphoblastic leukemia at diagnosis. Br Med J 1978;2:1529-30.
60. [60] Hart JS, Trujillo JM, Freireich EJ, et al. Cytogenetic studies and their clinical correlates in adults with acute leukemia. Ann Intern Med 1971;75:353-60.
61. [61] Mancini M, Nanni M, Cedrone M, et al. Combined cytogenetic, FISH, and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission. Br J Haematol 1995;91:878-84.
62. [62] Nowell P. Molecular monitoring of pre-B acute lymphoblastic leukaemia. J Clin Oncol 1987;5:692-3.
63. [63] Secker-Walker LM. Leukaemia Research Fund International Research Symposium: chromosomes and genes in leukaemia. Leukemia 1988;2:176-80.
64. [64] Johnson RT, Rao PN. Mammalian cell fusion: induction of premature chromosome condensation in interphase nuclei. Nature 1970;226:717-22.
65. [65] Hittelman WN, Broussard L, Dosik G, et al. Predicting relapse of human leukemia by means of premature chromosome condensation. New Engl J Med 1980;303:479-84.
66. [66] Barlogie B, Raber MN, Schumann J, et al. Flow cytometry in clinical cancer research. Cancer Res 1983;43:3982-8.
67. [67] Krishan A. Rapid cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 1975;66:188-93.
68. [68] Rabinovitch PS, Torres RM, Engel D. Simultaneous cell cycle analysis and two-color surface immunofluorescence using 7-aminoactinomycin D and single laser excitation: applications to study cell activation and cell cycle of murine Ly-B cells. J Immunol 1986;136:2769-75.
69. [69] Jensen IM, Ellegaard J, Hokland P. Differences in relative DNA content between human peripheral blood and bone marrow subpopulations - consequences for DNA index calculations. Cytometry 1993;14:936-42.
70. [70] Nowak R, Oelschlägel U, Hofmann R, et al. Detection of aneuploid cells in acute lymphoblastic leukemia with flow cytometry before and after therapy. Leuk Res 1994;18:897-901.
71. [71] Tsurusawa M, Kaneko Y, Katano N, et al. Flow cytometric evidence for minimal residual disease and cytological heterogeneities in acute lymphoblastic leukemia with severe hypodiploidy. Am J Hematol 1989;32:42-9.
72. [72] Arkesteijn GJA, Martens ACM, Hagenbeek A. Bivariate flow karyotyping in human Philadelphia-positive chronic myelocytic leukemia. Blood 1988;72:282.
73. [73] Gray JW, Kuo WL, Liang J, et al. Analytical approaches to detection and characterization of disease-linked chromosome aberrations. Bone Marrow Transpl 1990;6:14-9.
74. [74] Gray JW, Kuo WL, Pinkel D. Molecular cytometry applied to detection and characterization of disease-linked chromosome aberrations. Ballières Clin Haematol 1991;4:683-93.
75. [75] Chen Z, Morgan R, Berger CS, et al. Application of fluorescence in situ hybridization in hematological disorders. Cancer Genet Cytogenet 1992;63:62-9.
76. [76] Cuneo A, Bigoni R, Roberti MG, et al. Detection of numerical aberrations in hematologic neoplasias by fluorescence in situ hybridization. Haematology 1997;82:85-90.
77. [77] Pinkel D, Landegent J, Collins C, et al. Fluorescence in situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and translocations of chromosome 4. Proc Natl Acad Sci USA 1988;85:9138-42.
78. [78] Siciliano MJ. Fluorescence in situ hybridization: molecular cytogenetics. In: Kurzrock R, Talpaz M, editors. Molecular Biology in Cancer Medicine. London, UK: Dunitz, 1995:27-37.
79. [79] Heerema NA, Argyropoulas G, Weetman R, et al. Interphase in situ hybridization reveals minimal residual disease in early remission and return of the diagnostic clone in karyotypically normal relapse of acute lymphoblastic leukemia. Leukemia 1993;7:537-43.
80. [80] Anastasi J, Le Beau MM, Vardiman JW, et al. Detection of numerical chromosomal abnormalities in neoplastic hematopoietic cells by in situ hybridization with a chromosome-specific probe. Am J Pathol 1990;136:131-9.
81. [81] Nylund SJ, Ruutu T, Saarinen U, et al. Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haematopoietic malignancies. Br J Haematol 1994;88:778-83.
82. [82] Seong D, Giralt S, Fischer H, et al. Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia. Bone Marrow Transpl 1997;19:565-70.
83. [83] White DM, Crolla J, Ross F. Detection of minimal residual disease in childhood acute lymphoblastic leukaemia using fluorescent in situ hybridization. Br J Haematol 1995;95:1019-24.
84. [84] Kasprzyk A, Secker-Walker LM. Increased sensitivity of minimal residual disease detection by interphase FISH in acute lymphoblastic leukemia with hyperdiploidy. Leukemia 1997;11:429-35.
85. [85] Weber-Matthiesen K, Winkemann M, Müller-Hermelink A, et al. Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. J Histochem Cytochem 1992;40:171-5.
86. [86] Anastasi J, Vardiman JW, Rudinsky R, et al. Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: an analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia. Blood 1991;11:2456-62.
87. [87] Mehrotra B, George TI, Kavanau K, et al. Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. Blood 1995;86:1139-47.
88. [88] Tkachuk DC, Westbrook CA, Andreeff M, et al. Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. Science 1990;250:559-62.
89. [89] El-Rifai W, Ruutu T, Vettenranta K, et al. Minimal residual disease after alogeneic bone marrow transplantation for chronic myeloid leukemia: a metaphase-FISH study. Br J Haematol 1996;92:365-9.
90. [90] Arnoldus EPJ, Wiegant J, Noordermeer IA, et al. Detection of the Philadelphia chromosome in interphase nuclei. Cytogenet Cell Genet 1990;54:108-11.
91. [91] Raimondi SC. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993;81:2237-51.
92. [92] Estrov Z, Freedman MH. Growth requirements for human acute lymphoblastic leukemia cells: refinement of a clonogenic assay. Cancer Res 1988;48:5901-7.
93. [93] Ruey LH, Ssu WS, Ming TL, et al. Lymphoblast colony culture assay in acute lymphoblastic leukemia: a quantitative approach. Leuk Res 1993;17:463-70.
94. [94] Uckun FM, Kersey JH, Haake R, et al. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. New Engl J Med 1993;329:1296-301.
95. [95] Kurzrock R, Talpaz M, Beran M, et al. DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia. Leukemia 1998;12:242-6.
96. [96] Estrov Z, Ouspenskaia MV, Felix EA, et al. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia 1994;8:46-52.
97. [97] Miller CB, Zehnbauer BA, Piantadosi S, et al. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991;78:1125-31.
98. [98] Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975;98:503-17.
99. [99] Van Dongen JJM, Wolvers-Tettero ILM. Analysis of T immunoglobulin and T cell receptor genes. Part I: basic and technical aspects. Clin Chim Acta 1991;198:1-92.
100. [100] Cleary ML, Chao J, Warnke R, et al. Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Natl Acad Sci USA 1984;81:593-7.
101. [101] Yoffe G, Blick M, Kantarjian H, et al. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myelogenous leukemia. Blood 1987;69:961-3.
102. [102] Bregni M, Siena S, Neri A, et al. Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. J Clin Oncol 1989;7:338-43.
103. [103] Zehnbauer BA, Pardoll DM, Burke PJ, et al. Immunoglobulin gene rearrangements in remission bone marrow specimens from patients with acute lymphoblastic leukemia. Blood 1986;67:835-8.
104. [104] Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of β-globin genomic sequences and restriction site analysis of sickle cell anaemia. Science 1985;230:1350-4.
105. [105] Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487-91.
106. [106] d'Auriol L, Macintyre E, Galibert F, et al. In vitro amplification of T cell γ gene rearrangements: a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemia. Leukemia 1989;3:155-8.
107. [107] Hans en-Hagge TE, Yokota S, Bartram CR. Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor δ chain sequences. Blood 1989;74:1762-7.
108. [108] Yama da M, Hudson S, Tournay O, et al. Detection of minimal residual disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc Natl Acad Sci USA 1989;86:5123-7.
109. [109] Lee MS, Chang KS, Cabanillas F, et al. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 1987;237:175-8.
110. [110] Crescenzi M, Seto M, Herzig GP, et al. Thermostable DNA polymerase chain amplification of the t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci USA 1988;85:4869-73.
111. [111] White TJ, Arnheim N, Erlich HA. the polymerase chain reaction. Trends Genet 1989;5:185-9.
112. [112] Roberts WM, Estrov Z, Ouspenskaia MV, et al. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. New Engl J Med 1997;336:317-23.
113. [113] Sklar J. Polymerase chain reaction: the molecular microscope of residual disease. J Clin Oncol 1991;9:1521-4.
114. [114] Human Gene Mapping 8. Helsinki Conference: Eighth International Workshop on Human Gene Mapping. Cytogenet Cell Genet 1985;40:156-178, 206-241.
115. H families and linkage to the Ig CH locus. EMBO J 1988;7:727-39.
116. [116] Tonegawa S. Somatic generation of antibody diversity. Nature 1983;302:575-81.
117. [117] Abbas AK, Lichtman AH, Pober JS. Maturation of B lymphocytes and expression of immunoglobulin genes. In: Abbas AK, Lichtman AH, Pober JS, editors. Cellular and Molecular Immunology, 3rd edn. Philadelphia, PA: WB Saunders, 1997:67-95.
118. [118] Ichi hara Y, Matsuoka H, Kurosawa Y. Organization of human immunoglobulin heavy chain diversity gene loci. EMBO J 1988;7:4141-50.
119. [119] Bakkus MHC, Juge-Morineau N, Van der Werff ten Bosch JE. Detection of minimal residual disease in multiple myeloma and acute leukemia. Med Oncol 1996;13:121-31.
120. [120] Jonsson OG, Kitchens RL, Scott FC, et al. Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable specific oligonucleotide probes. Blood 1990;76:2072-9.
121. [121] Brisco MJ, Tan LW, Orsborn AM, et al. Development of a highly sensitive assay based on the polymerase chain reaction for rare B-lymphocyte clones in a polyclonal population. Br J Haematol 1990;75:163-7.
122. [122] Van Dongen JJM, Wolvers-Tettero ILM. Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin Chim Acta 1991;198:93-174.
123. [123] Felix CA, Poplack DG, Reaman GH, et al. Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol 1990;8:431-42.
124. [124] Beishuizen A, Verhoeven MA, Hahlen K, et al. Differences in immunoglobulin heavy chain gene rearrangement patterns between bone marrow and blood samples in childhood precursor B-acute lymphoblastic leukemia at diagnosis. Leukemia 1991;5:657-67.
125. [125] Breit TM, Wolvers-Tettero ILM, Beishuizen A, et al. Southern blot patterns, frequencies and junctional diversity of T-cell receptor d gene rearrangements in acute lymphoblastic leukemia. Blood 1993;82:3063-74.
126. [126] Katz F, Ball L, Gibbons B, et al. The use of DNA probes to monitor minimal residual disease in childhood acute lymphoblastic leukaemia. Br J Haematol 1989;73:173-80.
127. [127] Bird J, Galili N, Link M, et al. Continuing rearrangement but absence of somatic hypermutation in immunoglobulin genes of human B cell precursor leukemia. J Exp Med 1988;168:229-45.
128. [128] Beishuizen A, Verhoeven MAJ, van Wering ER, et al. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994;83:2238-47.
129. [129] Steward CG, Goulden NJ, Katz F, et al. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor δ gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 1994;83:1355-62.
130. [130] Biondi A, Di Celle PF, Rossi V, et al. High prevalence of T-cell receptor Vδ2-(D)-Dδ3 or Dδ1/2-Dδ3 rearrangements in B-precursor acute lymphoblastic leukemias. Blood 1990;75:1834-40.
131. [131] Norris MD, Kwan E, Haber M, et al. Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: a PCR-based assay employing overlapping DJh primers. Leukemia 1995;9:1779-82.
132. [132] Drexler HG, Borkhart A, Janssen JWG. Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Leuk Lymphoma 1995;19:359-80.
133. [133] Bartram CR. Detection of minimal residual leukemia by the polymerase chain reaction: potential implications for therapy. Clin Chim Acta 1993;217:75-83.
134. [134] Deane M, Hoffbrand AV. Detection of minimal residual disease in ALL. In: Freireich EJ, Kantarjian H, editors. Leukemia: Advances Research and Treatment. Dordrecht: Kluwer, 1993:136-70.
135. [135] Erlich HA, Gelfand DH, Saiki RK. Specific DNA amplification. Nature 1988;331:461-2.
136. [136] Chen Q, Cheng JT, Tsai LH, et al. The ta1 gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J 1990;9:415-24.
137. [137] Kagan J, Finger LR, Besa E, et al. Detection of minimal residual disease in leukemic patients with the t (10;14)(q24;q11) chromosomal translocation. Cancer Res 1990;50:5240-4.
138. [138] Maurer J, Janssen JWG, Thiel E, et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukemia by the polymerase chain reaction. Lancet 1991;337:1055-8.
139. [139] Kawasaki ES, Clark SS, Coyne MY, et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequence amplification in vitro. Proc Natl Acad Sci USA 1988;85:5698-702.
140. [140] Gehly GB, Bryant EM, Lee AM, et al. Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1991;78:458-65.
141. [141] Hunger SP, Galili N, Carroll AJ, et al. The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Blood 1991;77:687-93.
142. [142] Privitera E, Rivolta A, Ronchetti D, et al. Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia. Br J Haematol 1996;92:653-8.
143. [143] Cimino G, Elia L, Rivolta A, et al. Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive acute lymphoblastic leukaemia. Br J Haematol 1996;92:659-64.
144. [144] Shiramizu B, Magrath I. Localization of breakpoints by polymerase chain reactions in Burkitt's lymphoma with 8;14 translocations. Blood 1990;75:1848-52.
145. [145] Monica K, Galili N, Nourse J, et al. PBX2 and PBX3, new homeobox genes with extensive homology to the human protooncogene PBX1. Mol Cell Biol 1991;11:6149-57.
146. [146] Nakao M, Yokota S, Horiike S, et al. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia 1996;10:1463-70.
147. [147] Rayn aud S, Cavé H, Baens M, et al. The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996;87:2891-9.
148. [148] Billadeau D, Blackstadt M, Greipp P, et al. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood 1991;78:3021-9.
149. [149] Ouspenskaia MV, Johnston DA, Roberts WM, et al. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia 1995;9:321-8.
150. [150] Cross NCP, Feng L, Chase A, et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993;82:1929-36.
151. [151] Malinge MC, Mahon FX, Delfau MH, et al. Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukemia under interferon therapy. Br J Haematol 1992;82:701-7.
152. [152] Hughes T, Janssen JWG, Morgan G, et al. False-positive results with PCR to detect leukaemia-specific transcript. Lancet 1990; 335:1037-1038, letter.
153. [153] Ito Y, Miyamura K. Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure? Leuk Lymphoma 1994;16:57-64.
154. [154] Higuchi R. Simple and rapid preparation of samples for PCR. In: Erlich HA, editor. PCR Technology: Principles and Applications for DNA Amplification. New York, NY: Stockton Press, 1989:31-8.
155. [155] Sarkar G, Sommer SS. Shedding light on PCR contamination. Nature 1990;343:27.
156. [156] Rochelle P, Weightman AJ, Fry JC. Dnase I treatment of Taq DNA polymerase for complete PCR decontamination. Biotechniques 1992;13:520.
157. [157] Yokota S, Hansen-Hagge TE, Ludwig WD, et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 1991;77:331-9.
158. [158] Wasserman R, Galili N, Ito Y, et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992;10:1879-88.
159. [159] Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994;343:196-200.
160. [160] Steenbergen EJ, verhagen OJHM, van Leeuwen EF, et al. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia 1995;9:1726-34.
161. [161] Yama da M, Wasserman R, Lange B, et al. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. New Engl J Med 1990;323:448-55.
162. [162] Cole-Sinclair M, Foroni L, Wright F, et al. Minimal residual disease in acute lymphoblastic leukaemia - PCR analysis of immunoglobulin gene rearrangements. Leuk Lymphoma 1993; 11 (Suppl 2):49-58.
163. [163] Dibenedetto SP, Lo Nigro L, Pine Mayer S, et al. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. Blood 1997;90:1226-32.
164. [164] Neale GAM, Menarguez J, Kitchingman GR, et al. Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood 1991;78:739-47.
165. [165] Neale GAM, Pui CH, Mahmoud HH, et al. Molecular evidence for minimal residual bone marrow disease in children with 'isolated ' extramedullary relapse of T cell acute lymphoblastic leukemia. Leukemia 1994;8:768-75.
166. [166] Goulden N, Langlands K, Steward C, et al. PCR assessment of bone marrow status in 'isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukemia. Br J Haematol 1994;87:282-5.
167. [167] O'Reilly J, Meyer B, Baker D, et al. Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia. Leukemia 1995;15:624-7.
168. [168] Biondi A, Yokota S, Hansen-Hagge TE, et al. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 1992;6:282-8.
169. [169] Ito Y, Wasserman R, Galili N, et al. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J Clin Oncol 1993;11:546-53.
170. [170] Kitchingman GR. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia. Leukemia 1994;8:395-401.
171. [171] Kuang SQ, Gu LJ, Dong S, et al. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers. Cancer Genet Cytogenet 1996;88:110-7.
172. [172] Cortes JE, Kantarjian HM. Acute lymphoblastic leukemia. A comprehensive review with emphasis on biology and therapy. Cancer 1995;76:2393-417.
173. [173] Roberts WM, Estrov Z, Kitchingman R, et al. The significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification of antigen-receptor gene sequences. Leuk Lymphoma 1996;20:181-97.
174. [174] Nizet Y, Martiat P, Vaerman JL, et al. Follow-up of residual disease (MRD) in B-lineage acute leukemias using a simplified PCR strategy: evolution of MRD rather than its detection is correlated with clinical outcome. Br J Haematol 1991;79:205-10.
175. [175] Greaves M. Silence of the leukemic clone. New Engl J Med 1997;336:367-8.
176. [176] Gale RP, Butturini A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukemia. Lancet 1991;338:1315-8.
177. [177] Lanza C, Gottardi E, Gaidano G, et al. Persistence of E2A/PBX1 transcript in t(1;19) childhood acute lymphoblastic leukemia: correlation with chemotherapy intensity and clinical outcome. Leuk Res 1996;20:441-3.
178. [178] Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia M2 in long-term remission. Blood 1993;82:712-5.
179. [179] Chang KS, Fan YH, Stass SA, et al. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. Oncogen 1993;8:983-8.
180. [180] Birnie GD, MacKenzie ED, Goyns MH, et al. Sequestration of Philadelphia chromosome-positive cells in the bone marrow of a chronic myeloid leukemia patient in very prolonged remission. Leukemia 1990;4:452-4.
181. [181] Biernaux C, Loos M, Sels A, et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995;86:3118-22.
182. [182] Uhr JU, Scheuermann RH, Street N, et al. Cancer dormancy: opportunities for new therapeutic approaches. Nature Med 1997;3:505-9.
183. [183] Chessels JM, Hardisty RM, Richards S. Long survival in childhood lymphoblastic leukaemia. Br J Haematol 1987;55:315-9.
184. [184] Reynoso EE, Keating A, Baker MA. Acute leukemia occurring 19 years after treatment of acute lymphoblastic leukemia. Cancer 1987;59:1963-5.
185. [185] Nygard R, Moe PJ, Brincker H, et al. Late relapses after treatment for acute lymphoblastic leukemia in childhood: a population-based study from the nordic countries. Med Pediatr Oncol 1989;17:45-7.
186. [186] Frost L, Goodeve A, Wilson G, et al. Clonal stability in late-relapsing childhood lymphoblastic leukaemia. Br J Haematol 1997;98:992-4.
187. [187] Levasseur M, Maung ZT, Jackson G, et al. Relapse of acute lymphoblastic leukaemia 14 years after presentation: use of molecular techniques to confirm true re-emergence. Br J Haematol 1993;87:437-8.
188. [188] Wysocki M, Balcar-Borón A, Pilecki O, et al. Late relapse after presumed cure of childhood acute lymphoblastic leukemia. Acta Haematol Polonica 1993;24:381-4.
189. [189] Penn I. Cancers complicating organ transplantation. New Engl J Med 1990;323:1767-9.
190. [190] Bradstock KF, Gottlieb DJ. Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leuk Lymphoma 1995;18:1-16.
191. [191] Reaman GH, Poplack DG, Pizzo PA, et al. Late soft tissue recurrence of acute lymphoblastic leukemia in a site of antecedent trauma. J Pediatr 1978;92:849-50.
192. [192] Lundy J, Lovett EJ, Lipow D, et al. Anesthesia, surgery, immunosuppresion and tumor growth. In: Stewart THM, Wheelock EF, editors. Cellular Immune Mechanisms and Tumor Dormancy. Boca Raton, FL: CRC Press, 1992:155-67.
193. [193] Baker DL, Kees UR, Price PJ, et al. Late leukemic relapse 10 years from diagnosis in a child on recombinant human growth hormone. Pediatr Hematol Oncol 1993;10:55-62.
194. [194] Fisher DA, Job JC, Preece M, et al. Leukemia in patients treated with growth hormone. Lancet 1988;1:1159-60.
195. [195] Noble RL, Hoover LA. A classification of transplantable tumors in the Nb rats controlled by estrogen from dormancy to autonomy. Cancer Res 1975;35:2935-41.
196. [196] Strauss BS. The origin of point mutations in human tumor cells. Cancer Res 1992;52:249-53.
197. [197] Hall BG. Adaptive mutations in Escherichia coli - a model for the multiple mutational origins of tumors. Proc Natl Acad Sci USA 1995;92:5669-73.